{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:16:34Z","timestamp":1788833794491,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vaccine.2024.05.049","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T11:24:09Z","timestamp":1716549849000},"page":"126001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study"],"prefix":"10.1016","volume":"42","author":[{"given":"Theodoros","family":"Marantos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-517X","authenticated-orcid":false,"given":"Evdoxia","family":"Kyriazopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-5165","authenticated-orcid":false,"given":"Emmanouil","family":"Angelakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-9329","authenticated-orcid":false,"given":"Dimitrios","family":"Kitsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giota","family":"Mpizta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-2620","authenticated-orcid":false,"given":"Antonios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-5179","authenticated-orcid":false,"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0463-4321","authenticated-orcid":false,"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.05.049_b0005","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.05.049_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0015","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: from basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0020","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jech-2011-200168","article-title":"Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses","volume":"66","author":"Wotton","year":"2012","journal-title":"J Epidemiol Commun Health"},{"key":"10.1016\/j.vaccine.2024.05.049_b0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10654-019-00595-2","article-title":"Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway","volume":"35","author":"Ghaderi","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1212\/CPJ.0000000000001099","article-title":"Uptake and attitudes about immunizations in people with multiple sclerosis","volume":"11","author":"Marrie","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.vaccine.2024.05.049_b0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"French group for recommendations in multiple sclerosis (France4MS) and the soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques (SFSEP). immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.vaccine.2024.05.049_b0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2024.05.049_b0045","unstructured":"https:\/\/www.moh.gov.gr\/articles\/health\/dieythynsh-dhmosias-ygieinhs\/emboliasmoi\/ethniko-programma-emboliasmwn-epe-enhlikwn\/7968-ethniko-programma-emboliasmwn-enhlikwn-2020-2021. Last access: May 15, 2023."},{"key":"10.1016\/j.vaccine.2024.05.049_b0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0055","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0060","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718895","article-title":"Tetravalent influenza vaccine is not associated with neuroaxonal damage in multiple sclerosis patients","volume":"12","author":"Moser","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0070","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ene.15748","article-title":"Immunization status in patients with multiple sclerosis: a cross-sectional, monocenter study in Austria","volume":"30","author":"Berek","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0075","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/vaccines10071154","article-title":"Vaccine working group. influenza vaccination coverage among multiple sclerosis patients: evolution over time and associated factors","volume":"10","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.05.049_b0080","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3390\/vaccines10101766","article-title":"Influenza vaccination among multiple sclerosis patients during the COVID-19 pandemic","volume":"10","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.05.049_b0085","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13365-021-01011-w","article-title":"Influenza vaccination status in multiple sclerosis patients from Latin America","volume":"27","author":"Rojas","year":"2021","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103236","article-title":"Vaccine hesitancy among people with multiple sclerosis","volume":"56","author":"Yap","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.vaccine.2024.05.049_b0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7224\/1537-2073.2021-127","article-title":"Pneumococcal vaccination practices in patients with multiple sclerosis receiving anti-CD20 monoclonal antibodies after pharmacy and nursing collaboration","volume":"25","author":"Reindel","year":"2023","journal-title":"Int J MS Care"},{"key":"10.1016\/j.vaccine.2024.05.049_b0100","doi-asserted-by":"crossref","first-page":"2099171","DOI":"10.1080\/21645515.2022.2099171","article-title":"Vaccinations in patients with multiple sclerosis: a real-world, single-center experience","volume":"18","author":"Sbragia","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.049_b0105","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14740338.2022.2044787","article-title":"Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study","volume":"21","author":"Maniscalco","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.vaccine.2024.05.049_b0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.vaccine.2024.05.049_b0115","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2024.05.049_b0120","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.vaccine.2024.05.049_b0125","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1177\/13524585221099413","article-title":"Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis","volume":"28","author":"Schmierer","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2024.05.049_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.828616","article-title":"Vaccine response in patients with multiple sclerosis receiving teriflunomide","volume":"13","author":"Tornatore","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0135","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","article-title":"Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis","volume":"81","author":"Bar-Or","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2024.05.049_b0140","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0150","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2024.05.049_b0155","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","article-title":"Humoral immune response to influenza vaccine in natalizumab-treated MS patients","volume":"34","author":"V\u00e5gberg","year":"2012","journal-title":"Neurol Res"},{"key":"10.1016\/j.vaccine.2024.05.049_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.05.049_b0165","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.vaccine.2024.05.049_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102698","article-title":"Immunogenicity of the influenza vaccine in multiple sclerosis patients: a systematic review and meta-analysis","volume":"48","author":"Nguyen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.vaccine.2024.05.049_b0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1352458520952310","article-title":"Vaccinations in patients with multiple sclerosis: a Delphi consensus statement","volume":"27","author":"Riva","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2024.05.049_b0180","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.049_b0185","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:109-117.","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"10.1016\/j.vaccine.2024.05.049_b0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:08:47Z","timestamp":1737583727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24006170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0264410X24006170"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126001"}}